Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Aussie almonds reign supreme as Select Harvests boasts increased shipments and FTA with India
    • News

    Aussie almonds reign supreme as Select Harvests boasts increased shipments and FTA with India

    Have you been nuts about Aussie almonds lately? Turns out, so has the rest of the world.  Pointing to the Australian Almond Board Position Report for October (covering March to October), agribusiness company Select Harvests (ASX: SHV) has revealed that total year-to-date (YTD) shipments were up 9% on the prior year, while China YTD shipments

    Read More
    Public
  • Woolworth enters pet products retail market with PETstock acquisition
    • News

    Woolworth enters pet products retail market with PETstock acquisition

    It’s no secret that many Australians have filled the companion void throughout the pandemic with animal companionship, which has led Woolworth Group (ASX: WOW) to confirm its newest retail vertical by acquiring 55% of Petspiration Group – the owners of PETstock and it’s network of 276 stores across Australia and New Zealand.  Across its network

    Read More
    Public
  • Annoying coworker goes quiet after ATAR results reveal their son is an idiot
    • Satire

    Annoying coworker goes quiet after ATAR results reveal their son is an idiot

    For years, Martina Martinez has been so proud of her son’s extra curricular activities, boasting to the rest of the office about his Spanish lessons and self-sustaining veggie garden. So with ATAR results for Year 12 students released this week, the office was anticipating a flurry of chatter around Hugo’s prospects as a future surgeon,

    Read More
    Public
  • Pharmaxis cancer drug progress detailed at leading scientific conference, eyes FDA discussions in 2023
    • News

    Pharmaxis cancer drug progress detailed at leading scientific conference, eyes FDA discussions in 2023

    Having delivered impressive interim trial data from their Phase 2 clinical trials for a treatment targeting incurable bone marrow cancer, the US Food & Drug Administration (FDA) could soon be the next stop for biopharmaceuticals company Pharmaxis (ASX: PXS) fresh off their poster presentation at the American Society of Hematology (ASH) conference.  Hosted in New

    Read More
    Public
  • Landmark moment for Proteomics’s PromarkerD as it gets published in the UK’s NICE advice
    • News

    Landmark moment for Proteomics’s PromarkerD as it gets published in the UK’s NICE advice

    In the mood for some NICE advice? Here goes: The UK’s National Institute for Health and Care Excellence (NICE) has published a MedTech Innovation Briefing on PromarkerD, i.e. a predictive blood test determining diabetes kidney disease (DKD). The Briefing, dubbed NICE advice, reports that PromarkerD is effective at predicting renal function decline in people with

    Read More
    Public
  • Childcare provider observes rise in occupancy rate, but has it officially back to pre-pandemic level?
    • News

    Childcare provider observes rise in occupancy rate, but has it officially back to pre-pandemic level?

    If childcare occupancy rate is an indicator that the pandemic has come to an end, then the recent announcement from G8 Education (ASX: GEM) indicates that we are one step closer. The childcare education provider reported a core occupancy rate of 77.3%, which is a 1% improvement from CY21. This brings the company closer to

    Read More
    Public
  • «
  • ‹
  • 299
  • 300
  • 301
  • 302
  • 303
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.